ホジキンリンパ腫に対する一次治療としてのBV-AVD療法に伴う化学療法誘発性心毒性

Brentuximab vedotin (BV) with chemotherapy is a novel and an effective treatment for Hodgkin Lymphoma (HL) but is associated with increased rates of peripheral neuropathy and neutropenia. Since its increased use, novel adverse effects of the regimen have come to light, including unexpected toxicities. We report a case of BV-chemotherapy-induced cardiotoxicity, highlighting the need for vigilant monitoring and further research into the risk factors, mechanisms, and long-term safety profile of this therapy.